Small-molecule agents for cancer immunotherapy

Fang Wang(Jiangsu Province Hospital), Liwu Fu(Sun Yat-sen University), Yujue Wang(Center for Life Sciences), Kenneth K.W. To(Chinese University of Hong Kong), Zhi Shi(Jinan University), Chenglai Xia(Foshan Maternity and Child Health Care Hospital), Zeping Hu(King Center), Xiaopeng Li(University of South Florida), Zeyu Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xue‐Ping Wang(Sun Yat-sen University), Jianye Zhang(Shanghai Mental Health Center), Min Huang(First Affiliated Hospital of Wannan Medical College), Chuan Yang(Sun Yat-sen University), Kai Fu(Norwegian Womens Public Health Association), Yu Lu(State Key Laboratory of Respiratory Disease), Can Pan(Sun Yat-sen University), Ying Zheng(Chinese Academy of Sciences)
Acta Pharmaceutica Sinica B
December 15, 2023
10.1016/j.apsb.2023.12.010
Cited by 53

Related Papers

Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
KRAS mutation: from undruggable to druggable in cancer
|Signal Transduction and Targeted Therapy|2021|1k
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
|Cancer Research|2010|348
Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications
|Nature Communications|2021|319